[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.80 7.60 8.00 7.80 7.80 7.80 550,740 07:42:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.6 -1.0 - 12

N4 Pharma PLC Result of AGM

24/03/2021 10:45am

UK Regulatory (RNS & others)


N4 Pharma (LSE:N4P)
Historical Stock Chart


From Sep 2020 to Sep 2021

Click Here for more N4 Pharma Charts.

TIDMN4P

RNS Number : 3304T

N4 Pharma PLC

24 March 2021

24 March 2021

N4 Pharma plc

("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

 
  Resolution (*Special    Total Shares          Shares                 % 
       Resolution)            Voted 
                                            For       Against    For    Against 
                         -------------  -----------  --------  ------  -------- 
 
 1. To receive 
  the annual report 
  and audited accounts 
  for the year 
  ended 31 December 
  2020                     20,289,075    20,222,189   66,886    99.67    0.33 
                         -------------  -----------  --------  ------  -------- 
 2. To re-elect 
  Chris Britten 
  as a Director 
  of the Company           20,286,756    20,153,341   133,415   99.34    0.66 
                         -------------  -----------  --------  ------  -------- 
 3. To re-elect 
  Luke Cairns as 
  a Director of 
  the Company              20,286,756    20,194,827   91,929    99.55    0.45 
                         -------------  -----------  --------  ------  -------- 
 4. To re-elect 
  John Chiplin 
  as a Director 
  of the Company           20,286,756    20,209,370   77,386    99.62    0.38 
                         -------------  -----------  --------  ------  -------- 
 5. To re-appoint 
  Saffery Champness 
  LLP as auditor 
  to the company 
  and authorise 
  the directors 
  to determine 
  their remuneration       20,219,901    20,134,176   85,725    99.58    0.42 
                         -------------  -----------  --------  ------  -------- 
 6. To authorise 
  the Directors 
  to allot shares          20,283,475    20,101,362   182,113   99.10    0.90 
                         -------------  -----------  --------  ------  -------- 
 7* . To disapply 
  pre-emption rights       20,250,090    20,123,051   127,039   99.37    0.63 
                         -------------  -----------  --------  ------  -------- 
 

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                            Via IFC Advisory 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP                 Tel: +44(0)20 3470 
                                                 0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Rob Rees (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited          Tel: +44(0)20 3657 
                                                 0050 
 Joint Broker 
 Andy Thacker/Zoe Alexander 
 
 IFC Advisory Ltd                               Tel: +44(0)20 3934 
  Financial PR                                   6630 
  Graham Herring 
  Zach Cohen 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBGGDXBSDDGBS

(END) Dow Jones Newswires

March 24, 2021 06:45 ET (10:45 GMT)

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
N4P
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210927 22:49:29